Eli Lilly posts robust second-quarter sales results

Eli Lilly posted strong second-quarter sales results yesterday, despite a 19% net income drop due to charges and other items.

Lilly reported that its second-quarter sales rose to $4.63 billion from $3.87 billion.

Second-quarter highlights included:

*Sales of the Indianapolis drugmaker's best-selling product, the antipsychotic Zyprexa, which totaled $1.2 billion, a 9% increase compared with the second-quarter of 2006. U.S. sales of Zyprexa rose 4%, to $563.5 million. Zyprexa sales in international markets were up 14%, to $649.4 million.

*Sales of antidepressant Cymbalta, which generated $519.5 million, an increase of 67%. U.S. sales of Cymbalta were up 70% to $457.6 million. Sales outside the U.S. were $61.9 million, an increase of 53%.

* Sales of chemotherapy Gemzar, which totaled $395.6 million, an increase of 15%. Sales in the US were up 11% to $165.8 million, while sales outside the US rose 19%, to $229.8 million.

*Sales of osteoporosis treatment Evista, which totaled $278 million. US sales of Evista increased 1%, to $176.9 million. Sales outside the U.S. increased 1% to $101.1 million.

*Sales of Cialis for the second-quarter, which generated $293.1 million. Worldwide sales of Cialis grew 26%. US sales of Cialis were $110.2 million, a 17% increase.

*Worldwide sales of insulin Humulin, which increased 10% to $242.8 million.

*Sales of lung cancer treatment Alimta generated sales of $207.1 million, an increase of 35%. US sales of Alimta increased 22% to $107.4 million, while sales outside the U.S. increased 53%, to $99.7 million.

You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.